BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA

As part of a post-approval commitment requested by the Ministry of Food and Drug Safety (MFDS), this open-label, single-arm, multicentre, observational Post-Marketing Surveillance (PMS) study aims to characterize the safety profile of Breztri in real-world clinical practice settings, either confirming known safety outcomes or identifying previously unsuspected adverse drug reactions. The study will also evaluate effectiveness of Breztri in real-world clinical practice settings, generating essential clinical evidence from a broader and more diverse Korean patient population representative of daily medical practice.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Chronic Obstructive Pulmonary Disease (COPD) Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Sex eligibility

All sexes

Study type

Observational

About this study

This is an open-label, single-arm, multicentre, observational study. Eligible patients who initiate treatment with Breztri according to approved indications will be enrolled after obtaining informed consent. All patients treated (minimum 600 patients required) with Breztri in accordance with the local prescribing information are eligible for enrolment in this study. Initiation or continuation of Breztri prescription and patient enrolment will depend on physicians' medical decisions as per routine clinical practice. Approximately 30 study sites are expected to participate in this study.

As this study will be performed under clinical practice, the investigator may prescribe any other concomitant medications that are necessary for the patient as locally approved.

The total number of visits and the visit time will be determined at the discretion of the investigator based on the patient's condition.

Patients will be observed for up to 24 weeks. Follow-up will begin on the date of the first administration of Breztri (index date). However, if a patient is found to meet any of the exclusion criteria after enrolment, no additional follow-up (including the 30-day safety follow-up) will be conducted.

The primary objective of this study is to assess safety profile for patients receiving Breztri under the approved indication(s) in Korea.

The secondary objective of this study is to assess effectiveness for patients receiving Breztri under the approved indication(s) in Korea.

The exploratory objective of this study is to identify patients' baseline characteristics that might be associated with safety and effectiveness for patients receiving Breztri under the approved indication(s) in Korean patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who have been diagnosed with COPD.
Patients who have newly initiated treatment with Breztri according to the approved label in Korea
Provision of signed and dated written informed consent by the patient or legally acceptable representative

Exclusion criteria

Other off-label indications outside of the locally approved prescribing information
Pregnant and/or breast feeding
Current participation in any interventional trial

Treatment and study plan

Primary outcomes

Incidence proportion of Adverse Events (AEs)/Adverse Drug Reactions (ADRs)

Time frame: 24 weeks

All AEs/ADRs will be presented as the number of patients with an outcome of interest, the incidence proportion percentages, and the number of events, the corresponding Clopper-Pearson's two-sided 95% exact confidence interval (CI), and the number of events.
Incidence proportion of Serious AEs (SAEs)/Serious ADRs (SADRs)

Time frame: 24 weeks

SAEs/SADRs will be presented as the number of patients with an outcome of interest, the incidence proportion percentages, and the number of events, the corresponding Clopper-Pearson's two-sided 95% exact confidence interval (CI), and the number of events.
Incidence proportion of Unexpected AEs/Unexpected ADRs

Time frame: 24 weeks

Unexpected AEs/ADRs will be presented as the number of patients with an outcome of interest, the incidence proportion percentages, and the number of events, the corresponding Clopper-Pearson's two-sided 95% exact confidence interval (CI), and the number of events.
Incidence proportion of Unexpected SAEs/Unexpected SADRs

Time frame: 24 weeks

Unexpected SAEs/SADRs, will be presented as the number of patients with an outcome of interest, the incidence proportion percentages, and the number of events, the corresponding Clopper-Pearson's two-sided 95% exact confidence interval (CI), and the number of events.

Secondary outcomes

Change from baseline to week 12 and 24 in pre-dose Forced Expiratory Volume in 1 second (FEV₁)

Time frame: 12 or 24 weeks

Effectiveness analyses will be performed for effectiveness analysis population, defined as patients among the safety population who (i) have completed 12 or 24 weeks of treatment with Breztri, and (ii) have available FEV₁ data both at baseline (within 30 days prior to the first dose of Breztri) and at a visit occurring within 6 weeks prior to or subsequent to the 12- or 24-week treatment timepoint. If multiple measurements are available within this time window, the value closest to the 12- and 24-week target will be used.
Change from baseline to week 12 and 24 in COPD Assessment Test (CAT) score

Time frame: 12 or 24 weeks

Effectiveness analyses will be performed for effectiveness analysis population, defined as patients among the safety population who (i) have completed 12 or 24 weeks of treatment with Breztri, and (ii) have available CAT score data both at baseline (within 30 days prior to the first dose of Breztri) and at a visit occurring within 6 weeks prior to or subsequent to the 12- or 24-week treatment timepoint. If multiple measurements are available within this time window, the value closest to the 12- and 24-week target will be used.

Study contacts

Contact information is provided by the study sponsor or research team.

AstraZeneca Clinical Study Information Center

CONTACT

[email protected]

1-877-240-9479

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Acronym: Breztri rPMS

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: May 6, 2026
Registry last updated: May 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting